<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2186">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01454453</url>
  </required_header>
  <id_info>
    <org_study_id>2167SR</org_study_id>
    <nct_id>NCT01454453</nct_id>
  </id_info>
  <brief_title>Optimisation of Antipsychotic Drug Use in Older People</brief_title>
  <official_title>Rationalisation of Antipsychotic Drug Use in Older People, Using [18F]-Fallypride PET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Psychiatry, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Psychiatry, London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drugs such as amisulpride, known as antipsychotic drugs, are used to treat troublesome and&#xD;
      distressing symptoms in older people. Although these drugs can be beneficial, they are&#xD;
      associated with side effects, particularly in patients with dementia and schizophrenia- like&#xD;
      illness. There is an urgent clinical need to understand why this is the case, to guide&#xD;
      treatment strategies.&#xD;
&#xD;
      This study aims to utilise brain imaging techniques that measure the action of antipsychotic&#xD;
      drugs in the brain to explore the causes of this susceptibility in older people with dementia&#xD;
      and schizophrenia-like illness, and translate these findings into direct patient benefit.&#xD;
&#xD;
      The aim of the study is to investigate and compare the relationship between the action of&#xD;
      amisulpride at brain sites during the first 10 weeks of amisulpride treatment in two patient&#xD;
      groups - Alzheimer's disease and schizophrenia-like illness. Imaging data will be combined&#xD;
      with data on drug dosage, levels of drug in the bloodstream and clinical response (symptom&#xD;
      reduction and motor side effects) during dose titration.Dose-response modelling will be&#xD;
      carried out in both groups to establish the minimum clinically effective dose of amisulpride,&#xD;
      optimum dose range and impact of variability and covariates on exposure-response&#xD;
      relationships&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Failure to recruit people with very late onset schizophrenia like psychosis&#xD;
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dose titration</measure>
    <time_frame>12 weeks</time_frame>
    <description>receptor occupancy compared across 2 patient groups following dose-titration</description>
  </primary_outcome>
  <other_outcome>
    <measure>modelling of dose-response relationships</measure>
    <time_frame>12 weeks</time_frame>
    <description>dose-response modelling</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Patients - dose titration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amisulpride 50-200mg, 4-12 weeks, with brain imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patients- dose titration</intervention_name>
    <description>dose titration (patients) - 4-10 weeks</description>
    <arm_group_label>Patients - dose titration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Treatment and Control (antipsychotic free) Group&#xD;
&#xD;
        Schizophrenia&#xD;
&#xD;
          -  meet diagnostic criteria for schizophrenia-like illness&#xD;
&#xD;
          -  aged between 60 and 95 years of age&#xD;
&#xD;
          -  score &lt;6 on the Geriatric depression scale&#xD;
&#xD;
        Alzheimer's&#xD;
&#xD;
          -  meet diagnostic criteria for AD&#xD;
&#xD;
          -  score &lt;=4 on the Modified Hachinski Ischaemia Scale&#xD;
&#xD;
          -  score &lt; 8 on a modified version of the UPDRS&#xD;
&#xD;
          -  aged between 60 and 95 years of age&#xD;
&#xD;
          -  score &lt;6 on the Geriatric depression scale&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Treatment Group&#xD;
&#xD;
        Schizophrenia&#xD;
&#xD;
          -  current or past history of addiction, traumatic brain injury or epilepsy&#xD;
&#xD;
          -  prescribed any drug that interferes with brain dopamine in past 2 weeks (6 weeks if&#xD;
             depot antipsychotic medication).&#xD;
&#xD;
          -  medical conditions that might affect Ability to tolerate a brain scan&#xD;
&#xD;
          -  unable to give informed consent&#xD;
&#xD;
        Alzheimer's&#xD;
&#xD;
          -  current or past history of psychiatric illness, traumatic brain injury or epilepsy&#xD;
&#xD;
          -  prescribed an antipsychotic or other oral drug that interferes with brain dopamine&#xD;
             function within the past 2 weeks (6 weeks if depot antipsychotic medication).&#xD;
&#xD;
          -  medical conditions that might affect a person's ability to tolerate a brain scan&#xD;
&#xD;
        Control (antipsychotic free) Group&#xD;
&#xD;
        Schizophrenia&#xD;
&#xD;
          -  Prescribed psychotropic medication&#xD;
&#xD;
          -  unable to give informed consent&#xD;
&#xD;
        Alzheimer's&#xD;
&#xD;
        â€¢ Prescribed psychotropic medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne J Reeves, MBChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Psychiatry, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Psychiatry, Kings College London</name>
      <address>
        <city>London</city>
        <zip>SE58AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>October 12, 2011</study_first_submitted>
  <study_first_submitted_qc>October 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2011</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Psychiatry, London</investigator_affiliation>
    <investigator_full_name>Suzanne Reeves</investigator_full_name>
    <investigator_title>Clinician Scientist</investigator_title>
  </responsible_party>
  <keyword>amisulpride</keyword>
  <keyword>receptor occupancy</keyword>
  <keyword>antipsychotic sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

